Please assess the completion status of the following clinical trial:

Trial Title: An Open-label Continuation Trial to Assess the Continued Efficacy and Safety of Ascending Doses of Lacosamide in Subjects With Chronic Refractory Neuropathic Pain

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is informed and given ample time and opportunity to think about her/his participation in this extension trial and has given her/his written informed consent~* Subject met all inclusion criteria defined in the SP611 trial with SPM927 at the time of enrollment into trial SP611~* Subject has successfully completed trial SP611 and, in the investigator's opinion, would benefit from long-term administration of SPM927~* Subject is willing and able to comply with all trial requirements, including the ability to complete trial questionnaires~Exclusion Criteria:~* Subject previously participated in this trial~* Subject has participated in another trial of an investigational drug within the last 3 months (excluding trial SP611) or is currently participating in another trial of an investigational drug~* Subject has had prior therapy with a Nonsteroidal Anti-inflammatory Drug (NSAID) or Anti-epileptic Drug (AED) within 28 days prior to the Eligibility Visit~* Subject has evidence or history of significant Cardiovascular Disease within 12 months prior to the Eligibility Visit~* Subject has laboratory values, which are outside the normal range and judged by the Investigator to be clinically significant~* Subject has abnormal Renal or Hepatic function~* Subject has a history of Malignancies with the exception of subjects with a documented disease-free interval of 5 years or more~* Subject has a history of chronic alcohol or drug abuse within the last 12 months~* Subject has any medical or psychiatric condition which, in the opinion of the Investigator, could jeopardize or compromise the subject's ability to participate in this continuation trial~* Subject with a known history of severe Anaphylactic Reaction and/or serious or life threatening Blood Dyscrasias

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lacosamide (Type: EXPERIMENTAL): Open-label active treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).